Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Xeris Pharmaceuticals (Nasdaq: XERS) will release its Q3 2020 financial results on November 9, 2020, prior to the U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss financial and operational outcomes. As a specialty pharmaceutical company, Xeris focuses on innovative drug formulations to improve therapy administration. Notably, its proprietary platforms provide room-temperature stable injectable therapies, streamlining use for patients and healthcare providers.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) has granted non-qualified stock options totaling 36,250 shares to 15 new employees as part of its Inducement Equity Plan. This plan provides equity awards to individuals not previously employed by Xeris, incentivizing them to join the company. The stock options will vest over four years, with various vesting schedules based on continued employment. Xeris leverages innovative technology to simplify injectable and infusible drug formulations, with its first commercial product being Gvoke®.
Xeris Pharmaceuticals (Nasdaq: XERS) has received FDA Fast Track designation for XP-0863, a non-aqueous injectable formulation of diazepam aimed at treating acute repetitive seizures. This designation underscores the urgent need for improved treatments in this area. Xeris plans to partner with a development firm to expedite the product's evaluation and delivery. Current data suggests a significant percentage of epilepsy patients are uncontrolled on oral therapies, highlighting the market potential for XP-0863. The company is also advancing towards a Phase 3 study following positive feedback from the FDA.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of non-qualified stock options totaling 250 shares to a new employee on September 30, 2020. This grant was made under Xeris’ Inducement Equity Plan, designed for individuals not previously employed by the company. The options will vest over four years, with structured timelines based on continued employment. Xeris aims to simplify therapy administration through innovative, ready-to-use formulations, enhancing patient experience and healthcare system efficiency.